Knott David M Jr Has $47,000 Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Knott David M Jr cut its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 93.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,005 shares of the company’s stock after selling 57,578 shares during the quarter. Knott David M Jr’s holdings in Roivant Sciences were worth $47,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after purchasing an additional 1,507 shares during the period. Quarry LP lifted its position in Roivant Sciences by 50.0% in the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after buying an additional 2,500 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Roivant Sciences by 550.1% during the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock valued at $91,000 after buying an additional 6,667 shares during the period. Finally, HighTower Advisors LLC purchased a new position in shares of Roivant Sciences during the 4th quarter valued at $121,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Roivant Sciences

In other news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was acquired at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the acquisition, the director now owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Eric Venker sold 218,041 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the completion of the transaction, the chief operating officer now owns 896,869 shares in the company, valued at $9,345,374.98. The trade was a 19.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,395,541 shares of company stock worth $15,028,538 over the last 90 days. Insiders own 7.90% of the company’s stock.

Wall Street Analysts Forecast Growth

ROIV has been the subject of several recent research reports. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Roivant Sciences presently has an average rating of “Buy” and an average price target of $17.10.

Roivant Sciences Trading Down 2.8 %

Shares of NASDAQ:ROIV opened at $10.09 on Tuesday. Roivant Sciences Ltd. has a 1 year low of $9.92 and a 1 year high of $13.06. The firm has a fifty day moving average price of $10.72 and a 200 day moving average price of $11.38. The stock has a market capitalization of $7.20 billion, a PE ratio of -67.26 and a beta of 1.26.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, sell-side analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.